利伐沙班治疗效果怎么样呢？

Rivaroxaban is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). So, how effective is rivaroxaban?

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets.

A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans. The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants. In patients undergoing major orthopedic surgery, 5/95th (percentile) PT was (NeopLastin) 13-25 seconds 2-4 hours after taking the tablet (when the effect is strongest) (baseline value before surgery was 12-15 seconds).

Be aware of the risk of bleeding while taking rivaroxaban:

Some subgroups of patients are at higher risk of bleeding. After initiation of treatment, these patients should be monitored closely for signs of bleeding complications. This can be accomplished by regular physical examination of the patient, close observation of surgical wound drainage, and regular determination of hemoglobin. Any unexplained decrease in hemoglobin or blood pressure should prompt a search for the site of bleeding.

In terms of usage and dosage, the recommended dose is 10 mg of oral rivaroxaban, once a day. If the wound has stopped bleeding, the first medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone.